MMRF Statement on FDA Approval of TECVAYLI™, the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
October 26, 2022
View
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
October 25, 2022
FDA OKs Teclistamab for Relapsed/Refractory Multiple Myeloma
2022 Accelerator
September 30, 2022
IMS Studies Utilize CoMMpass Genomic Data in Multiple Myeloma Research
August 31, 2022
Day 2 Highlights from the 19th International Myeloma Society Annual Meeting
August 27, 2022
Day 1 Highlights from the 19th International Myeloma Society Annual Meeting
August 26, 2022
MMRF CoMMpass and MyDRUG Studies Drive Discoveries in Research Presented at 19th IMS Annual Meeting
August 24, 2022
Researchers Find Potential Link Between Genetic Mutations and Treatment Resistance in Patients With Relapsed or Refractory Multiple Myeloma
July 28, 2022
Answers to 3 FAQs from our 6/29/22 Expert Session on Myeloma Highlights from the 2022 ASCO Meeting
July 5, 2022
MMRF Virtual ASCO 2022 Meeting Blogs
June 9, 2022
Extraordinary Healer Award: An Angel to Patients With Cancer
May 9, 2022
Knowledge is power. Sign up today and we’ll help you stay informed.
sign up
We value your privacy.
